ClinicalTrials.gg
RecruitingNCT07247968Updated Jan 7, 2026

Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study

An Early Phase 1 interventional study of Esketamine injection group (0.25 mg/kg) and Saline injection group (Consistent with esketamine injection volume) in Esketamine, ECT and Depression, sponsored by Min Su. Recruiting at 2 sites in China. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Min Su · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
13 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies testing esketamine in Depression — 11 open to participants now, 12 under way, 1 of them phase 3. Esketamine · Depression.

Planned enrollment
10th of 28
220 · median 156
Started
2025
with 1 other
Phase 1
4 of 28
2 open now
Primary completion
2026-11
later than 6 of 11 live
Registered
24th of 28
by date

Among the 28 studies testing esketamine in Depression, this one is the 10th largest by planned enrollment, is one of 2 that started in 2025, is one of 4 in phase 1, reaches primary completion later than 6 of the 11 other live ones, and was the 24th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

11 of the 28 studies testing esketamine in Depression are open now, in 3 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About esketamine

Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 13 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing esketamine in Depression, or all of them as a file.
02

Study summary

The study design was a randomized, double blind, parallel controlled trial.The goal of this clinical trial is to learn if esketamine-assisted modified electroconvulsive therapy (ESK-MECT) works to treat severe depression in adolescents. It will also learn about the safety of ESK-MECT.

The sample size was calculated based on the response rate of patients with depression undergoing electroconvulsive therapy(ECT).According to the results of the pilot study,the efficacy rate of subjects receiving adjunctive esketamine was approximately 78%,while the efficacy rate of those receiving only propofol was 63%.The expected superiority difference in remission rates between the two groups was 15%(one-sided)for the power calculation.Assuming a significance level of α=0.05 and a test power of β=0.2,with a 1:1 ratio of sample sizes between the two groups,the total sample size was calculated to be 198 using the PASS software(PASS 2023).Considering a dropout rate of 10%,a total of 220 subjects were required,with 110 subjects in each group.

  1. experimental group The patients were given intravenous injection of 0.25 mg / kg esketamine, 1.5 mg / kg propofol and 1 mg / kg succinylcholine in turn. After anesthesia, the patients were given electroconvulsive therapy.
  2. In the control group The patients were given normal saline consistent with esketamine injection volume, 1.5mg/kg of propofol and 1mg / kg of succinylcholine. After anesthesia, the patients were given electroconvulsive therapy.

Efficacy evaluation 1. Main efficacy indicators Response rate of depressive symptoms after MECT treatment Response is defined as two consecutive HAMD-24 scores ≤ 50% before treatment after receiving MECT treatment. The response rate is calculated as the number of patients who achieved as response divided by the total number of patients receiving MECT.In this study, the 24-item version of HAMD was utilized.

Participants will:

Be randomly assigned to the esketamine group or the control group, and receive standard MECT treatment.

Have seizure parameters, seizure duration, vital signs, and complications recorded.

Complete psychiatric scale assessments, including HAMD-24, BSS, PANSS, WMS-RC and MoCA.

Be assessed at the following time points: HAMD-24 and BSS after each treatment; PANSS after each treatment course;WMS-RC and MoCA before MECT and after one treatment course.

All subjects did not discontinue antidepressants before modified electroconvulsive therapy(MECT),and they were fasting for 8 hours and no fluids for 2 hours.Three minutes before MECT,continuous qCON monitoring(Apollo-9000A,Chongqing Xideer Medical Equipment Co.,Ltd.,China)was initiated,while monitoring blood pressure,heart rate,and peripheral capillary oxygen saturation.Preoxygenation was administered for 3 minutes.The qCON monitor uses three electrodes on the forehead to collect raw electroencephalogram(EEG)signals.The qCON monitoring includes the qCON index,qNOX index,burst suppression(BS),and signal quality index(SQI).

03

Conditions studied

  • Esketamine
  • ECT
  • Depression
  • Adolescent

Browse trials for

04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inpatients diagnosed with Major Depressive Disorder according to the International Classification of Diseases,11th Revision(ICD-11),and scheduled for Modified Electroconvulsive Therapy(MECT);
  • Aged 13 to 17 years,regardless of gender;
  • Educational attainment of primary school or higher;
  • Normal hearing and vision,including color perception;
  • Voluntary participation in the study with signed ;
  • (ASA)physical status classification I-II.

Exclusion criteria

Exclusion Criteria:

  • Severe cardiovascular disease,significant arrhythmias,or other cardiac conditions;
  • Inability to complete the assessment scales;
  • History of substance abuse;
  • Received electroconvulsive therapy(ECT)within 6 months prior to the study;
  • Severe cerebrovascular disease,severe hypertension,intracranial hypertension,or presence of intracranial electrodes;
  • Severe allergy or to propofol or succinylcholine;
  • Comorbid with other psychiatric disorders.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Esketamine injection group (0.25mg/kg)

    The main anesthesiologist standing on the right side of the patient gave successive injections of esketamine (0.25 mg/kg), and 1 minute later, injected propofol (1.5mg/kg) for 30 s.After the loss of consciousness, all patients were administered 1 mg/kg of succinylcholine chloride and manually ventilated with a face mask until they regained full consciousness.

    Drug: Esketamine injection group (0.25 mg/kg)

  • Sham comparator
    Saline injection group(Consistent with esketamine injection volume)

    The main anesthesiologist standing on the right side of the patient gave successive injections of saline (Consistent with esketamine injection volume), and 1 minute later, injected 1.5mg/kg of propofol in 30s.After the loss of consciousness,all patients were administered 1 mg/kg of succinylcholine chloride and manually ventilated with a face mask until they regained full consciousness.

    Other: Saline injection group (Consistent with esketamine injection volume)

Interventions

  • DrugEsketamine injection group (0.25 mg/kg)

    Drug page: EsketamineStudies of EsketamineEsketamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The main anesthesiologist standing on the right side of the patient injects esketamine (0.25 mg/kg) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later for 30 s.After the loss of consciousness,all patients were administered 1 mg/kg of succinylcholine chloride and manually ventilated with a face mask until they regained full consciousness.

  • OtherSaline injection group (Consistent with esketamine injection volume)

    The main anesthesiologist standing on the right side of the patient injects saline (Consistent with esketamine injection volume) sequentially, and then propofol (1.5 mg/kg) is injected 1 minute later, the injection time is 30s.After the loss of consciousness,all patients were administered 1 mg/kg of succinylcholine chloride and manually ventilated with a face mask until they regained full consciousness.

06

What researchers measure

Primary outcomes

  1. Treatment response rate

    Response is defined as two consecutive HAMD-24 scores ≤ 50% before treatment after receiving MECT treatment. The response rate is calculated as the number of patients who achieved as response divided by the total number of patients receiving MECT.In this study, the 24-item version of HAMD was utilized.

    Time frame: immediately after the end of each MECT procedure

Secondary outcomes

  1. Remission rate of depressive symptoms after MECT treatment

    Remission is defined as a sustained HAMD scores below 10 points for two consecutive times. In this study, the 24-item version of HAMD was utilized.The remission rate is calculated as the number of patients who achieved remission divided by the total number of patients receiving MECT.

    Time frame: immediately after the end of each MECT procedure

  2. Changes in cognitive function

    Cognitive function changes were evaluated using the Montreal Cognitive Assessment (MoCA) scales before MECT and at the end of MECT course.

    Time frame: Immediately after the end of MECT course

  3. The remission rate of suicidal ideation

    Suicidal ideation were evaluated using the the Beck Scale for Suicidal Ideation.The remission rate of SI is calculated as the number of patients with SI remission after MECT divided by the total number of patients with SI.

    Time frame: through treatment completion, an average of 18 days

  4. Changes in psychiatric symptoms

    Changes in psychotic symptoms that accompany depression during treatment were assessed using the Positive and Negative Syndrome Scale(PANSS) after each MECT session.

    Time frame: Immediately after the end of MECT course

  5. Wechsler Memory Scale-Chinese-Revision

    The Wechsler Memory Scale-Chinese-Revision(WMS-RC)was used to assess patients'learning and memory functions before and at the end of Modified Electroconvulsive Therapy(MECT).

    Time frame: Immediately after the end of MECT course

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data(IPD)is detailed information collected from each study participant.There are several reasons why IPD might not be shared: Privacy and Confidentiality Concerns Personal Identifiable Information:IPD contains sensitive information like medical history and genetic data.Sharing it without safeguards can violate privacy and lead to issues like discrimination. Regulatory Requirements:Laws like GDPR require strict handling of personal data.Sharing IPD without proper anonymization and consent can result in legal problems. Intellectual Property and Commercial Interests Research Investment:Generating IPD requires significant resources.Researchers may want to control the data to fully exploit it for further research and publications. Patent and Licensing Issues:Premature sharing of IPD can affect patentability and licensing agreements. Data Integrity and Misuse Quality Control:Shared IPD can be misinterpreted by others who lack context,leading

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 11 months after the start.

Of 82 non-industry phase 1 interventional studies under Depression, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 61. This study's planned 11 months is below that.

Counting every sponsor, half of 102 studies reached it within 27 months; a quarter within 11 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Nov 25, 2025
StartActual
Nov 25, 2025
Primary completionEst.
Nov 20, 2026
CompletionEst.
Dec 20, 2026
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07247968
Lead sponsor
Min Su
Responsible party
Min Su (Professor of Anesthesiology, First Affiliated Hospital of Chongqing Medical University) — Sponsor-investigator
First posted
Nov 25, 2025
Start date
Nov 25, 2025
Primary completion
Nov 20, 2026 (estimated)
Completion
Dec 20, 2026 (estimated)
Last update
Jan 7, 2026

Study contacts

Xiaoge Han, Master
Contact
3164233689@qq.com
023-89011061
Su Min
principal investigator · First Affiliated Hospital of Chongqing Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion